(Q33477635)

27 July 2017

title

The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial (English)

1 reference

27 July 2017

8

Benjamin Haibe-Kains

0 references

Christine Desmedt

object named as

Christine Desmedt

1

0 references

Giuseppe Viale

9

object named as

Giuseppe Viale

1 reference

27 July 2017

Marie-Rose Christiaens

5

object named as

Marie-Rose Christiaens

1 reference

27 July 2017

3

Patrick Neven

1 reference

27 July 2017

7

Françoise Lallemand

1 reference

27 July 2017

12

Christos Sotiriou

1 reference

27 July 2017

2

Anita Giobbie-Hurder

1 reference

27 July 2017

Robert Paridaens

4

1 reference

27 July 2017

Ann Smeets

6

1 reference

27 July 2017

Richard D Gelber

10

1 reference

27 July 2017

Martine Piccart

11

1 reference

27 July 2017

publication date

2 July 2009

1 reference

27 July 2017

1 reference

27 July 2017

volume

2

1 reference

27 July 2017

page(s)

40

1 reference

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole

27 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713270

Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713270

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713270

What do we know about the mechanisms of aromatase inhibitor resistance?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713270

Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713270

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713270

Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713270

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713270

Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1755-8794-2-40

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1755-8794-2-40

Survival model predictive accuracy and ROC curves

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1755-8794-2-40

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1755-8794-2-40

Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1755-8794-2-40

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1755-8794-2-40

Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19573224

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1755-8794-2-40

1 reference

Dimensions Publication ID

27 July 2017

0 references

1 reference

27 July 2017

1 reference